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RESEARCH ARTICLE
EFFECTS OF GROWTH HORMONE ON MUSCLE STRENGTH, TONE 
AND MOBILITY OF CHILDREN WITH PRADER-WILLI SYNDROME  
Abstract
Objective
Prader-Willi Syndrome (PWS) is a genetic syndrome presenting with severe 
hypotonia and decreased agility. Growth Hormone (GH), which is often used 
in these patients to treat short stature and obesity, seems improve hypotonia, 
physical strength, activity, and locomotor developmental ability. The aim of 
this study was to find the effects of growth hormone on agility and strength of 
these patients.
Material & Methods
In a prospective randomized controlled clinical trial in an out-patient pediatric 
endocrine clinic in Tehran, 21 PWS children (12 boys and 9 girls, 4 to 9 years 
old) were divided into either GH-treated or control groups and followed for two 
years. Agility run, sit ups, weight lifting, and inspiratory and expiratory strength 
were considered as the main outcome measures. 
Results
All the outcome measures of the GH treated group showed a significant 
improvement compared to the control group.
Conclusion
GH causes a significant improvement in agility and strength of PWS children.
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Introduction
Prader-Willi Syndrome (PWS), initially described in 1956, is now known to be 
caused by a deletion of the paternal allele in position 15q11–13 (~70% of patients) or 
a uniparental (maternal) disomy, affecting the same region or the whole chromosome 
15 (1). Thus, PWS is a manifestation of genomic imprinting; the critical region of 
chromosome 15 is active only in the paternally inherited chromosome. Affected 
children are characterized by distinct facies, obesity, hypotonia, short stature, 
hypogonadism, and behavioral abnormalities (2). With an incidence of 1 in every 
12,000 births, PWS is the most common syndromal cause of marked obesity.
Many features of PWS suggest hypothalamic dysfunction, some with endocrine 
implications including hyperphagia, sleep disorders, deficient growth hormone (GH) 
secretion, and hypogonadism (3–5). Growth of children with PWS is characterized 
by moderate intrauterine (average –1standard deviation score [SDS]) and postnatal 
growth delay. Usually, after the age of 2 or 3, when caloric intake increases and 
obesity begins to develop, growth rates become normal.However, catch-up in 
length/height relationship is less common. The hands and feet of these children 
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tend to be particularly small. Childhood growth rates 
are close to normal, but lack of normal pubertal growth 
often results in reduced adult stature (mean 146 cm for 
adult PWS female, 152 cm for adult PWS male). The 
slow growth and delayed skeletal maturation observed 
in some, but not all, PWS children contrasts with healthy 
obese children, in whom growth acceleration and bone 
age advancement are commonly seen with overnutrition. 
Growth impairment in PWS cannot be attributed to 
any known intrinsic bone or cartilage abnormality. 
Consequently, attention has focused on possible defective 
hypothalamic regulation of the growth process. Growth 
hormone responses to insulin, arginine, clonidine, 
L-dopa, or GH releasing hormone (GHRH) are reported 
to be low normal or blunted in PWS, as are sleep-induced 
GH secretion and 24-h integrated GH concentrations 
(3-6). Studies on consecutive patients with PWS have 
revealed GH levels <10 ng/mL following clonidine 
provocation in all patients (6-9).
Hypotonia is prenatal in onset, and is usually manifested 
as decreased fetal movement, abnormal fetal position 
at delivery, and increased need for assisted delivery 
or cesarean section. In infancy, there is decreased 
movement and lethargy with decreased spontaneous 
arousal, weak cry, and poor reflexes, including a poor 
suck that leads to early feeding difficulties and poor 
weight gain. Deep tendon reflexes are often spared. 
Assisted feeding through a feeding tube and/or special 
nipples with increased feeding times are invariably 
necessary. The hypotonia is central in origin. Mild-to-
moderate hypotonia persists throughout life. Hypotonia 
is so characteristic that all newborns with unexplained 
persistent hypotonia should be tested for PWS (9, 10). 
Gross motor and language milestones are delayed. Early 
milestones are reached on average at double the normal 
age (eg, sitting at 12 months, walking at 24 months, 
and words at 2 years). Cognitive disability is evident by 
school age. Most people with PWS are mildly mentally 
retarded (mean IQ: 60–70s), with approximately 40% 
having borderline mental retardation or low-normal 
intelligence and approximately 20% having moderate 
retardation. Regardless of measured IQ, most people 
with PWS have multiple severe learning disabilities and 
poor academic performance for their mental abilities. 
Articulation is poor. Most adults require sheltered 
residential and employment settings because of a 
combination of cognitive, behavioral and food-seeking 
characteristics (9, 10).
Most studies reported structural and functional muscle 
abnormalities in PWS: morphological  abnormalities of 
contractile elements and mitochondria, type-2 muscle 
fiber atrophy, with type-2B fiber deficiency and increased 
immature type-2C muscle fibers decreased type-1 
muscle fiber size, decreased CoQ10 levels in muscle 
tissue indicating abnormal mitochondrial function, 
and decreased strength of thoracic muscles and knee 
flexor and Only one study reported hypo-excitability 
of the cortical motor areas. Based on these preliminary 
results, it can be hypothesized that the clinical symptoms 
originate at least partly from innate cortical and/or muscle 
pathology and partly from a secondary phenomenon of 
disuse. Therefore, more research is necessary to study the 
relationship between clinical symptoms, hypotonia and 
decreased muscle mass and strength, and the presence of 
structural and functional abnormalities in muscles and 
motor cortex (11, 12).
Substantial information is accumulating to support 
beneficial effects of 12–36 months of GH therapy 
on improving body composition and linear growth 
in children with Prader-Willi Syndrome (PWS). 
However, perhaps of greatest importance to patients 
and their families is the hope that GH therapy would 
improve the child’s physical strength, activity, and 
developmental ability. Early reports include anecdotal 
reports of dramatic gains in physical activity abilities, 
and many parents of our subjects also claimed striking 
improvements in physical stamina, strength, and agility. 
Specifically, they included new gross motor skills (e.g., 
independently climbing up the bus steps, carrying a 
medium-sized bag, and participating in a normal gym 
class without restrictions).
Materials & Methods
Twenty-two PWS children (12 boys and 10 girls, age 
range: 4 to 9 years) were selected among PWS patients 
who referred to a tertiary out-patient pediatric endocrine 
clinic in Tehran, and divided into two groups: 11 children 
(6 boys and 5 girls) received subcutaneous growth 
hormone [PEN NORDILET; Novonordisk 5 IU/ 1.5 
ml] (1 mg/ per one square meter of body surface area) 
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every night for two years, while11 children (7 boys and 4 
girls) in the control group did not receive any medication 
throughout the study. 
The thyroid function test, standard growth hormone 
stimulation test with clonidine, and bone age 
determination with Greulich and Pyle method were 
done in all patients before starting the study. All cases 
were genetically proven to be PWS either either FISH or 
by LINKAGE studies. All the measures were obtained 
and recorded by 2 pediatric endocrinologists and one 
physiotherapist throughout the study.
All patients in the controlled group were examined 
by a pediatric neurologist and an otolaryngologist for 
possible risk of sleep apnea following the administration 
of growth hormone. We evaluated the patients every 
3 months for their growth indexes, possible adverse 
effects of GH, and also the specific outcome measures 
of the study.
We used the objective measures of changes in physical 
function during GH treatment, including a timed run 
(second), broad jumps (cm), sit-ups (in 20 seconds), 
and weight lifting (kg by reps) (5-9). We also measured 
respiratory muscle forces including inspiratory and 
expiratory strengths (cm/H2O) using a spirometeric 
device.
Two patients dropped out (a girl in the growth hormone 
group due to disagreement of the parents, and a boy in 
the control group due to the emigration of the family), 
both in the first months of study. 
We informed all the parents regarding possible hazards 
of therapy and obtained the written consent of the parents 
before starting the study. The study was conducted with 
the approval of the ethics committee of Pediatric Surgery 
Research Center of Mofid Children’s Hospital and under 
the guidelines of the Declaration of Helsinki.
Results
There was no significant difference between the possible 
confabulating factors including age, height standard 
deviation score (HeightSDS), height standard deviation 
score of Prader-Willi patients (HeightSDSPWS), body 
mass index (BMI), body mass index of Prader-Willi 
patients, and insulin like growth factor 1- standard 
deviation score (IGF-I SDS) between the case and 
control groups at the beginning of the study (p< 0.001) 
(Table 1).
Missing data analysis showed no significant difference in 
results after omitting the drop-out cases from the study.
 Improvements in the speed of running, broad jump, 
sit-ups and arm curls after 12 months of GH treatment 
compared to controls were documented. Following 
24 months of GH treatment, improvements in broad 
jumping and sit-ups were maintained, while further 
improvement was noted in running speed and arm curls 
(Table 2). Measurement of respiratory muscle forces 
was reliably obtained in these individuals. Increases 
in both respiratory muscle forces were seen after one 
year of therapy and maintained at 24 months (Table 
2). Additionally, strength and agility data at 24 months 
significantly increased compared to 12-month data, as 
well as significant improvement compared to prior to 
GH therapy (Fig. 1).
Discussion
Our study showed a significant improvement in running 
speed, broad jump, sit ups and arm curls after 12 months 
of GH administration which was similar to Angulo, 
Myers and Carel studies (3, 5-9). On the other hand, 
we followed the patients for 24 months (12 months 
more). We found the broad jumping improved slightly 
but still significantly (p<0.05), although sit ups showed 
an insignificant increase between 12 and 24 months 
(p=0.02). 
Motor problems in Prader-Willi Syndrome (PWS) are 
presumably related to abnormal body composition and 
certain neuromuscular abnormalities. Increased fat mass 
and decreased lean body mass are characteristics of 
PWS. As a result, muscle mass is decreased by 25-37%, 
which might explain partly the weakness and hypotonia. 
However, there are also structural and functional muscle 
abnormalities, and cortical motor areas are hypo-
excitable in PWS patients. Moreover, disuse, as a result 
of decreased activity in PWS, could also contribute. GH 
treatment positively influences body composition, but 
does not normalize it. Training could prevent disuse and 
improves body composition. Therefore, GH treatment 
and training will probably enhance each other (12).
Although there are studies showing that growth hormone 
therapy causes an increased basal metabolic rate and 
oxygen consumption, and hence increases ventilatory 
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load which may elevate the risk of sleep apnea in these 
patients(13), our study showed significant increases in 
both respiratory (inspiratory and expiratory) muscle 
forces throughout the study, which was similar to the 
results of Myers et al. (7). Recently, Carrel et al. found 
that in contrast to significant improvements observed 
during the initial 24 months of GH therapy (5, 6), 
strength, and agility, neither improved nor regressed 
during an additional 24 months of GH therapy at any 
dose (6).
In spite of these gains in physical function, PWS children 
still remain less compared to non-PWS children for all 
studied parameters. While lack of a blinded, placebo-
controlled study design admittedly weakens scientific 
validity of these findings, they do suggest that measured 
improvements in strength and agility are associated with 
“real-life” functional benefits to the children and their 
families. 
However, the insight in the origin of severe motor 
problems and hypotonia, decreased muscle mass and 
strength in PWS children were not discussed in this study. 
On the other hand, it seems that the research on body 
composition and the effect of GH has brought a lot of 
benefits to patients with PWS in managing the imbalance 
between fat mass and LBM, which has a positive effect on 
motor performance and fitness in general.
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Fig1. GH therapy in PWS patients: Agility Run
